10-Q: James River Group Reports Q2 Loss, Strategic Shift

James River Group Holdings, Ltd. reported a significant decline in net income and EPS for Q2 2025, alongside strategic de-risking actions and a reduced common share dividend.

Summary

• Net income available to common shareholders decreased by 44.2% to $2.8 million for the three months ended June 30, 2025, compared to $5.0 million in the prior year period.
• For the six months ended June 30, 2025, net income available to common shareholders fell 41.5% to $10.4 million, down from $17.8 million in the same period last year.
• Underwriting profit for the three months ended June 30, 2025, increased by 69.3% to $2.1 million, with a combined ratio of 98.6%, an improvement from 99.3% in the prior year quarter.
• However, underwriting profit for the six months ended June 30, 2025, decreased by 70.2% to $2.8 million, with a combined ratio of 99.1%, worsening from 97.2% in the prior year period.
• Gross written premiums declined by 8.3% to $378.0 million for the three months and 9.5% to $672.4 million for the six months ended June 30, 2025, primarily due to a 35.0% and 32.9% decrease in the Specialty Admitted Insurance segment, respectively.
• Net investment income decreased by 17.7% to $20.5 million for the three months and 14.8% to $40.5 million for the six months ended June 30, 2025, driven by lower invested assets and yields.
• The sale of JRG Re, comprising the former Casualty Reinsurance segment, closed on April 16, 2024, with a final downward adjustment of $483,625 paid to Fleming on April 29, 2025.
• A new $212.5 million unsecured revolving credit facility was entered into on June 12, 2025, replacing the previous facility, with $210.8 million drawn at June 30, 2025.
• The U.S. District Court, Southern District of New York, granted the Company's motion to dismiss the lawsuit filed by Fleming on July 17, 2025.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to significant declines in net income, EPS, and a substantial reduction in common share dividends. While strategic actions like the JRG Re sale, new credit facility, and favorable lawsuit dismissal are positive for long-term stability and risk management, the immediate financial performance is a clear step down, impacting shareholder returns.

Positives

• Underwriting profit for the three months ended June 30, 2025, increased by 69.3% to $2.1 million, reflecting improved underwriting performance in the Excess and Surplus Lines segment.
• The combined ratio improved to 98.6% for the three months ended June 30, 2025, from 99.3% in the prior year quarter, indicating better underwriting profitability.
• The loss ratio improved to 68.1% for the three months and 67.4% for the six months ended June 30, 2025, primarily due to less net adverse reserve development on prior accident years.
• The Company successfully dismissed the lawsuit filed by Fleming against JRG Holdings and certain officers on July 17, 2025, reducing legal uncertainty.
• A new $212.5 million unsecured revolving credit facility was secured, enhancing liquidity and capital flexibility.
• The sale of JRG Re was finalized, completing the disposition of the casualty reinsurance business and allowing for a more focused strategic direction.
• Growth in tangible common equity was 5.3% for the quarter and 12.8% for the six months ended June 30, 2025, largely driven by net income and unrealized gains on fixed maturities.

Negatives

• Net income available to common shareholders significantly decreased by 44.2% for the three months and 41.5% for the six months ended June 30, 2025.
• Basic and diluted earnings per common share declined substantially for both the three-month ($0.06 basic, $0.06 diluted) and six-month ($0.23 basic, $0.22 diluted) periods compared to the prior year.
• Gross written premiums decreased by 8.3% for the three months and 9.5% for the six months ended June 30, 2025, primarily due to non-renewals in the Specialty Admitted Insurance segment.
• Net investment income declined by 17.7% for the three months and 14.8% for the six months ended June 30, 2025, due to lower invested assets and yields.
• The expense ratio increased to 30.5% for the three months and 31.7% for the six months ended June 30, 2025, reflecting higher expenses and lower net earned premium.
• The common share dividend was significantly reduced to $0.01 per share for Q2 2025, down from $0.05 per share in Q2 2024.
• The Specialty Admitted Insurance segment reported underwriting losses of $1.4 million for the three months and $1.7 million for the six months ended June 30, 2025, compared to profits in the prior year periods.

Risks

• Inherent uncertainty in estimating reserves, with the possibility that incurred losses may exceed current estimates.
• Potential for inaccurate estimates and judgments in risk management, leading to greater unintended risks.
• Risk of downgrades in the financial strength rating or outlook of regulated insurance subsidiaries, impacting competitive position and business attraction.
• The outcome of ongoing litigation related to the sale of the casualty reinsurance business, despite a recent favorable dismissal.
• Potential loss of key management or employees and challenges in attracting and retaining personnel.
• Adverse economic and competitive factors that could lead to fewer policy sales or an increase in claims frequency or severity.
• Impact of higher than expected inflation on reserves, loss adjustment expenses, investment values, and compensation costs.
• Exposure to credit risk, interest rate risk, and other market risks within the investment portfolio and with reinsurers.
• Reliance on a select group of brokers, agents, and customers for a significant portion of business, and the risk of failing to maintain these relationships.
• Challenges in obtaining adequate insurance and reinsurance coverage at favorable prices and terms.
• Risk of losses if reinsurance counterparties, fronting arrangements, or indemnification parties fail to meet their obligations.
• Inherent uncertainty in estimating reinsurance recoverable on unpaid losses.
• Inadequacy of premiums charged to cover incurred losses.
• Changes in laws or government regulations, including tax or insurance laws, which could retroactively impact the company.
• Potential for the company or its foreign subsidiary to become subject to U.S. federal income taxation, increasing the tax rate.
• Failure of loss limitations or exclusions in insurance products to protect against unanticipated financial or legal liabilities.
• Losses from catastrophic events (e.g., natural disasters, terrorist acts) exceeding expectations or reinsurance coverage.
• Potential business impacts from emerging claim and coverage issues.
• Risks associated with internal or external fraud, operational errors, system malfunctions, or cyber security incidents.
• Challenges in effectively managing company growth.
• Failure to maintain effective internal controls in accordance with the Sarbanes-Oxley Act.
• Restrictions on subsidiaries' ability to pay dividends due to changes in financial condition or regulations.
• Credit exposure to Rasier and Aleka under Indemnity Agreements and the Commercial Auto LPT if estimated losses grow faster than collateral balances or if estimates are lower than actual amounts paid.

Future Outlook

The company expects to continue considering opportunities consistent with its fiduciary duty following the completion of its strategic review process. Management does not intend to sell available-for-sale securities currently in an unrealized loss position and does not expect to be required to sell them before a recovery in their value to amortized cost occurs. The company's long-term incentive plan is designed to align compensation of senior officers with company performance and shareholder interests over the long-term, with performance periods extending through December 31, 2027 for the latest awards.

Management Comments

• Our objective is to consistently earn underwriting profits.
• We evaluate the performance of our segments and allocate resources based primarily on the potential for underwriting profit.
• Management believes that the lack of economic impact of retroactive reinsurance accounting makes the presentation of our key metrics on business not subject to retroactive reinsurance accounting helpful to the users of our financial information.
• Given changes in our underwriting appetite, we are being selective in certain lines of business.
• The Company's strategy is to remain opportunistic in the current market environment and manage the Specialty Admitted Insurance segment to retain minimal risk.
• Management does not intend to sell available-for-sale securities in an unrealized loss position, and it is not more likely than not that the Company will be required to sell these securities before a recovery in their value to their amortized cost basis occurs.
• The Board of Directors concluded the strategic review process announced in November of 2023. While the strategic review process has been completed, in the ordinary course of business the Company and Board of Directors expect to consider opportunities consistent with its fiduciary duty.

Industry Context

The company operates within the specialty insurance market, which often allows for more tailored risk pricing and potentially higher margins compared to standard lines. The decline in net investment income reflects broader market trends of fluctuating interest rates and investment returns. The strategic shift away from casualty reinsurance and the focus on managing risk in the Specialty Admitted Insurance segment indicate a move towards a more focused and potentially less volatile business model, aligning with a trend among insurers to shed non-core or underperforming assets to improve capital efficiency and risk profiles.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• The company filed a complaint against Fleming in the Supreme Court of the State of New York on March 11, 2024, alleging breach of the Stock Purchase Agreement for the sale of JRG Re and seeking specific performance and damages. The court granted the company's motion for preliminary injunction on April 6, 2024, ordering Fleming to complete the transaction by April 16, 2024. Fleming's appeal was withdrawn on October 9, 2024. Fleming filed motions to dismiss the company's complaints, which are ongoing.
• Fleming filed a lawsuit against JRG Holdings and certain officers in the U.S. District Court, Southern District of New York, on July 15, 2024, asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, common law fraud, and breaches of contract related to the JRG Re sale. The company's motion to dismiss this lawsuit was granted by the court on July 17, 2025. Fleming has until August 18, 2025, to file a notice of appeal.

Related Party Transactions

• Series A Preferred Shares are held by GPC Partners Investments (Thames) LP, an affiliate of Gallatin Point Capital LLC.
• The Commercial Auto Loss Portfolio Transfer (LPT) was entered into with Aleka Insurance, Inc., a captive insurance company affiliate of Rasier LLC, to reinsure commercial auto policies.
• The company has indemnity agreements with Rasier (non-insurance entities) for reimbursement of losses and expenses on Rasier Commercial Auto Policies.
• An Adverse Development Cover (E&S Top Up ADC) was entered into with Cavello Bay Reinsurance Limited, a subsidiary of Enstar Group Limited. Enstar also purchased $12.5 million of the company's common shares.

Stakeholder Impact

• **Shareholders**: Experienced a significant reduction in net income and earnings per share, along with a substantial cut in common share dividends, negatively impacting immediate returns. However, strategic de-risking through the JRG Re sale and adverse development covers, coupled with the favorable dismissal of a major lawsuit, could improve long-term stability and shareholder value.
• **Employees**: The company continues to offer equity incentive plans (RSUs, PRSUs) designed to align compensation with company performance. Richard J. Schmitzer's retirement and the ongoing succession planning indicate management transition.
• **Customers/Policyholders**: The company's focus on specialty insurance niches and selective underwriting, supported by strong reinsurance programs (including new ADCs), aims to ensure continued capacity and claims-paying ability. The A.M. Best A(Excellent) rating supports confidence in the insurance subsidiaries.
• **Reinsurers**: Key relationships with State National and Enstar (Cavello Bay) are critical for risk transfer and capital management, indicating continued reliance on strong reinsurance partnerships.
• **Creditors**: The new unsecured revolving credit facility and compliance with financial covenants demonstrate the company's ability to manage its debt obligations and maintain access to capital, which is positive for creditors.

Next Steps

• Richard J. Schmitzer will assist in the transition of his responsibilities as principal executive officer of James River Insurance Company and James River Management Company, Inc. through his retirement date.
• The company and Richard J. Schmitzer will negotiate a new title and adjusted compensation for his modified duties after July 31, 2025.
• Fleming has until August 18, 2025, to file a notice of appeal regarding the dismissal of their lawsuit against the company.
• Common share dividends of $0.01 per share are payable on September 30, 2025, to shareholders of record on September 15, 2025.
• Series A Preferred Shares dividends of up to $2.0 million are payable on September 30, 2025, to shareholders of record on September 15, 2025.
• Awards under the 2014 LTIP and 2014 Director Plan, approved on July 24, 2025, will have grant dates of August 6, 2025, and July 24, 2025, respectively.

Key Dates

Recommendation

The company's Q2 2025 results show a significant decline in net income and EPS, coupled with a substantial reduction in common share dividends, which are clear negative signals for investors. While underwriting profit improved for the quarter, the six-month combined ratio worsened, and investment income is down. However, the company has made significant strategic moves to de-risk and streamline its operations, including the successful sale of JRG Re and securing new adverse development covers. The recent dismissal of a major lawsuit against the company is also a positive development, reducing legal overhang. Given the mixed financial performance but positive strategic direction and de-risking efforts, a 'hold' recommendation is appropriate. Existing investors should monitor the execution of the strategic plan and the stabilization of financial results, while new investors might await more consistent positive trends before initiating a position.

Keywords

Specialty Insurance, Excess and Surplus Lines, Reinsurance, Financial Results, Underwriting Profit, Combined Ratio, Investment Income, SEC Filing, Insurance Holdings, Risk Management, Casualty Insurance, Financial Strength Rating